Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for Uterine Receptivity in RIF
NCT03237117Phase 1Unknown
- Sponsor
- Competence Centre on Health Technologies
- Start
- Jan 2010
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of somatropin in female infertility and Recurrent Implantation Failure (RIF), sponsored by Competence Centre on Health Technologies. Primary endpoint: Pregnancy rate. Status: unknown.
02
Drugs
somatropin
03
Conditions
female infertilityRecurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT03237117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237117.